Ultralife Corporation
ULBI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.82 | 0.01 | -6.51 |
| FCF Yield | 0.00% | 3.24% | 2.76% | 1.97% |
| EV / EBITDA | -142.35 | 54.82 | 27.80 | 68.43 |
| Quality | ||||
| ROIC | -0.35% | 0.90% | 1.34% | 0.36% |
| Gross Margin | 22.18% | 23.89% | 25.12% | 24.17% |
| Cash Conversion Ratio | -0.14 | 6.75 | 1.81 | 15.70 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.49% | 7.51% | 9.11% | 7.65% |
| Free Cash Flow Growth | 0.00% | 95.51% | 1.35% | -41.23% |
| Safety | ||||
| Net Debt / EBITDA | 7.22 | 12.42 | 9.29 | 18.94 |
| Interest Coverage | -0.96 | 2.27 | 3.29 | 1.78 |
| Efficiency | ||||
| Inventory Turnover | 0.64 | 0.73 | 0.79 | 0.65 |
| Cash Conversion Cycle | 167.06 | 146.46 | 137.93 | 160.97 |